The agent storefront at https://agents.pubrio.com/llms.txt?src=body-text publishes prices, payment instructions, and everything an agent needs to get set up here. Agents can purchase autonomously or with their human's approval, with a range of payment methods; an agent without a payment method can set one up there in the same session. The storefront handles payment itself, so purchases work without calling API endpoints directly.
Scholar Rock is a biopharmaceutical company that discovers, develops, and delivers life-changing therapies for people with serious diseases that have high unmet need. As a global leader in the biology of the transforming growth factor beta (TGFβ) superfamily of cell proteins and named for the visual resemblance of a scholar rock to protein structures, the clinical-stage company is focused on advancing innovative treatments where protein growth factors are fundamental. Over the past decade, the company has created a pipeline with the potential to advance the standard of care for neuromuscular disease, cardiometabolic disorders, cancer, and other conditions where growth factor-targeted drugs can play a transformational role. Scholar Rock is the only company to show clinical proof of concept for a muscle-targeted treatment in spinal muscular atrophy (SMA). This commitment to unlocking fundamentally different therapeutic approaches is powered by broad application of a proprietary platform, which has developed novel monoclonal antibodies to modulate protein growth factors with extraordinary selectivity. By harnessing cutting-edge science in disease spaces that are historically under-addressed through traditional therapies, Scholar Rock works every day to create new possibilities for patients. Learn more about the company’s approach at ScholarRock.com and follow @ScholarRock on X. For additional information on our guidelines, please visit https://scholarrock.com/community-guidelines/ For more information on how Scholar Rock collects, uses, and shares personal information, please visit: https://scholarrock.com/privacy-policy/
解锁市场时间线与信号动态
最近 90 天内有 3 个信号。
该公司进入各个市场的顺序 — 从最早到最新
Director, International Indirect Tax
Director, International Indirect Tax
注册以查看完整信号动态
Scholar Rock 的国际扩张与竞争对手的对比情况
Scholar Rock你条形图显示所对比公司之间的相对规模。
5 项指标| 公司 | 市场 | 新市场 | 势头 | 活动 | 扩张评分 |
|---|---|---|---|---|---|
 Scholar Rock你 | 2 | 0 | +100% | 3 | 23 |
快速扩张——最近 90 天新增 23 个职位，较上一周期增长 56%。 以 Clinical Systems 为主，集中在 美国。
Dublin, County Dublin, Ireland · 今天
Director, International Indirect Tax
Cambridge, MA · 3天前
Associate Director, IT Service Delivery & Support
Cambridge, MA · 3天前
Sr. Director, Infrastructure & Operations
在技术栈中检测到 34 项技术。
没有进行中的营销活动
注册以跟踪该公司，并在发生变化时第一时间获得提醒。
最近 90 天获 2 次提及。
Scholar Rock首席执行官David Hallal表示,公司正处于强势地位,进入SMA社区的关键时期,生物制剂许可申请正在进行中。
Scholar Rock举行2026年第二季度业绩电话会议,高管讨论业务更新、研发进展、商业准备和财务业绩。
解锁已验证邮箱与直拨电话
免费 · 无需信用卡
关于 Scholar Rock 的业务、市场和增长信号的快速解答。
